Mode of action of Van-M-02, a novel glycopeptide inhibitor of peptidoglycan synthesis, in vancomycin-resistant bacteria

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 960-962

  Miura, Kenji ^a   Yamashiro, Hidenori ^a   Uotani, Kouichi ^a   Kojima, Satoshi ^a   Yutsudo, Takashi ^a   Lu, Jun ^b,d   Yoshida, Osamu ^a   Yamano, Yoshinori ^a   Maki, Hideki ^a   Arimoto, Hirokazu ^c  

^a SHIONOGI AND CO LTD   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PEPTIDOGLYCAN; PROTEIN SYNTHESIS INHIBITOR; UNCLASSIFIED DRUG; VAN M 02; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; IC 50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS; GLYCOPEPTIDES; LIPID METABOLISM; MOLECULAR STRUCTURE; PEPTIDOGLYCAN; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 75749108294     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00927-09     Document Type: Article

References (12)

1. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb. Mortal. Wkly. Rep. 51:565-567.
2. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, M7-A7. 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Fairweather, N., S. Kennedy, T. J. Foster, M. Kehoe, and G. Dougan. 1983. Expression of a cloned Staphylococcus aureus alpha-hemolysin determinant in Bacillus subtilis and Staphylococcus aureus. Infect. Immun. 41:1112-1117.
4. Foucault, M. L., P. Courvalin, and C. Grillot-Courvalin. 2009. Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:2354-2359.
5. Hunt, G. A., and A. J. Moses. 1958. Acute infection of mice with Smith strain of Staphylococcus aureus. Science 128:1574.
6. Kerns, R., S. D. Dong, S. Fukuzawa, J. Carbeck, J. Kohler, L. Silver, and D. Kahne. 2000. The role of hydrophobic substituents in the biological activity of glycopeptide antibiotics. J. Am. Chem. Soc. 122:12608-12609.
7. Lentino, J. R., M. Narita, and V. L. Yu. 2008. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur. J. Clin. Microbiol. Infect. Dis. 27:3-15.
8. Lu, J., O. Yoshida, S. Hayashi, and H. Arimoto. 2007. Synthesis of rigidlylinked vancomycin dimers and their in vivo efficacy against resistant bacteria. Chem. Commun. (Camb.) 21:251-253.
9. Maki, H., K. Miura, and Y. Yamano. 2001. Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45:1823-1827.
10. Rotun, S. S., V. McMath, D. J. Schoonmaker, P. S. Maupin, F. C. Tenover, B. C. Hill, and D. M. Ackman. 1999. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg. Infect. Dis. 5:147-149.
11. Schneider, T., M. M. Senn, B. Berger-Bachi, A. Tossi, H. G. Sahl, and I. Wiedemann. 2004. In vitro assembly of a complete, pentaglycine interpeptide bridge containing cell wall precursor (lipid II-Gly5) of Staphylococcus aureus. Mol. Microbiol. 53:675-685.
12. Sievert, D. M., J. T. Rudrik, J. B. Patel, L. C. McDonald, M. J. Wilkins, and J. C. Hageman. 2008. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin. Infect. Dis. 46:668-674.